Medicamenteuze behandeling van hartfalen: Een herwaardering van bètablokkers, spironolacton en digoxine

Huisarts en Wetenschap

Volumn 43, Issue 4, 2000, Pages 163-166

  Geijer, R M M ^a   Walma, E P ^a  

^a DUTCH COLLEGE OF GENERAL PRACTITIONERS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; SPIRONOLACTONE;

CARDIOVASCULAR EFFECT; DISEASE CLASSIFICATION; DRUG EFFICACY; HEART FAILURE; HUMAN; SHORT SURVEY; TREATMENT PLANNING;

EID: 0034129060     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Walma EP, Bakx HCA, Besselink RAM, et al. NHG-Standaard Hartfalen. Huisarts Wet 1995; 38:471-87.
2. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274: 1462-7.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity in patients with chronic heart failure. N Engl J Med 1996;334: 1349-55.
4. Heidenreich PA, Lee TT, Massie BM, et al. Effects of betablockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials L Am Coll Cardiol 1997;30:27-34.
5. Sharpe N. Benefit of _-blockers for heart failure: proven in 1999. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
6. MERIT-HF Trial Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
7. Cleland JGF, McGowan J, Clark A. The evidence for β blockers in heart failure. Equals or surpasses that for angiotensin converting enzyme inhibitors. BMJ 1999;318:824-5.
8. Pfeffer MA, Stevenson LW. β-adrenergic blockers and survival in heart failure. N Engl J Med 1996;334:1396-7.
9. Rayburn BK. Carvedilol reduced mortality and hospitalization in chronic heart failure. Evidence-Based Medicine 1996;2:212-3.
10. Tan LB, Murphy R. Shifts in mortality curves: saving or extending lives? Lancet 1999;454:1378-81.
11. Gottlieb SS, McCarter RJ, Vogel RA. Effect of betablockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
13. Van Guldener C, Donker AJM. Anti-aldosteron therapie bij ernstig hartfalen. Ned Tijdschr Geneesd 1999;143:1724-5.
14. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753-5.
15. Richards AM, Nicholls MG. Aldosterone antagonism in heart failure. Lancet 1999;354:789-90
16. The digitalis investigation group. The effect of digoxin on mortality an morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
17. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis. N Engl J Med 1997;336:575-6.